Clinical Trial

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.
Trial Details
NCT Number NCT07090954
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Multiple Myeloma
Enrollment 32 participants
Start Date 2025-08-31
Primary Completion 2026-07-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-29